Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kidofen Duo is a prescription pediatric oral suspension developed by Aflofarm Farmacja Polska that combines two active ingredients: ibuprofen (100 mg) and paracetamol (125 mg) per 5 ml. It is indicated for the short-term treatment of fever and mild to moderate pain of various origins (including post-operative pain) in children aged 2 years and older, particularly when monotherapy with paracetamol or ibuprofen is insufficient. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins. Paracetamol acts as an analgesic and antipyretic, with a mechanism of action thought to involve the inhibition of COX-3 in the central nervous system. The product is marketed as the first such combination in a pediatric suspension form in Europe.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kidofen Duo.